Radiation therapy fractionation in the modern era of head and neck oncology towards an improved therapeutic window
Academia Oncology · 2024
DOI: 10.20935/acadonco7352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Academia Oncology, 2024. Verfasst von Loredana G. Marcu. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 85 Literaturangaben.
Abstract (Originalsprache)
The importance of fractionation in radiotherapy has been known since the early days of radiobiology. Certain tumors, such as head and neck, are radiobiologically challenging because of several factors contributing to treatment failure, including hypoxia, cellular kinetics, and proportion of cancer stem cells. The management of the above factors often requires different, more aggressive approaches, which led to the design of altered fractionation schedules. Despite these unconventional treatment regimens, the clinical outcome of head and neck cancer patients has not significantly improved. Therefore, there is the need for combined modality treatments employing chemo- and/or immunotherapy. Furthermore, proton therapy and hadrontherapy are trialed in this patient group to elucidate their advantage over conventional techniques. This article discusses all the above aspects in the context of fractionation and also the evolution and impact of fractionated regimens on the clinical outcome of head and neck cancer patients.
Zitieren
APA
Marcu, L. G. (2024). Radiation therapy fractionation in the modern era of head and neck oncology towards an improved therapeutic window. Academia Oncology. https://doi.org/10.20935/acadonco7352
Vancouver
Marcu LG. Radiation therapy fractionation in the modern era of head and neck oncology towards an improved therapeutic window. Academia Oncology. 2024. doi:10.20935/acadonco7352
BibTeX
@article{Marcu2024,
author = {Marcu, Loredana G.},
title = {Radiation therapy fractionation in the modern era of head and neck oncology towards an improved therapeutic window},
journal = {Academia Oncology},
year = {2024},
doi = {10.20935/acadonco7352}
}
EUVIMED